文献速递其他结缔组织病

印度北部特发性炎性肌病早期死亡率高:三级中心起始队列结果

High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究基于印度北部三级中心的起始队列,纳入70例特发性炎性肌病患者,随访10个月发现15.2%死亡,1年生存率在抗MDA5亚型为30%、抗合成酶综合征亚型为75%。下呼吸道感染、恶性肿瘤和快速进展型间质性肺病是主要死因,老龄和抗MDA5阳性预测死亡。

要点

  • 印度IIM患者早期死亡率高达15.2%,主要死因为感染、癌症和RP-ILD。
  • 抗MDA5亚型1年生存率仅30%,抗合成酶综合征亚型为75%。
  • 老龄和抗MDA5阳性是死亡的独立预测因素。

核心结论

  • 印度IIM患者早期死亡率高,归因于感染、癌症和快速进展型间质性肺病。
  • 自身抗体和某些临床特征可识别复合不良结局风险。

研究设计与样本

  • 随访10(4-15)个月,评估早期结局包括死亡、IMACS核心指标和复合不良结局。

主要发现

  • 70例患者中10例(15.2%)死亡,4例多发性肌炎被重新分类。
  • 皮肌炎是最常见亚型(成人29例,41.4%;儿童7例,87.5%)。
  • 下呼吸道感染是最常见死因(3例,30%),其次为恶性肿瘤和RP-ILD。
  • 存活者中54.5%成人及100%儿童达到主要IMACS反应,30%有中重度残疾,16.7%复发。
  • 三分之二患者发生复合不良结局。

关键数值与推荐

  • 抗MDA5亚型1年生存率为30%,抗合成酶综合征亚型为75%。
  • 多变量分析显示老龄和抗MDA5阳性预测死亡。
  • 关节炎、皮疹和ANA阳性降低复合不良结局风险,抗MDA5增加该风险。

临床怎么用

  • 对IIM患者诊断后应高度警惕感染、恶性肿瘤和RP-ILD,尤其抗MDA5阳性或老龄患者。
  • 利用自身抗体和临床特征(关节炎、皮疹、ANA)识别复合不良结局高风险患者。

局限性

  • 单中心起始队列,样本量70例,随访时间短(中位10个月)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We determined the mortality along with the proportion of disease related adverse events measured individually and by a composite adverse outcome (devised by including deaths, disability, relapses and minimal response) and its predictors in an inception cohort of idiopathic inflammatory myopathies (IIM). METHODS: IIM from the MyoCite cohort (December 2017-19) were reviewed for early outcomes (mortality, IMACS core set). Comparisons were drawn between those meeting the primary and secondary outcomes. RESULTS: Of 70 patients [62 adults, M:F = 1:4.8, age 43 (28.5-51) and eight children, M:F = 1:1, 14.5 (8.8-16)], dermatomyositis (DM) was the most common subset [29 (41.4%) adults; 7 (87.5%) children]. Over 10 (4-15) months, 10 (15.2%) died and four polymyositis were reclassified. One-year survival for anti-melanoma differentiation antigen 5 (MDA5) subtype was 30% and anti-synthetase syndrome (ARS) subtype was 75%. Overall, lower respiratory infections were the most common cause of death [n = 3 (30%)] followed closely by malignancy and rapidly progressive interstitial lung disease (RP-ILD). Amongst survivors, a major IMACS response was recorded in 54.5% adults and 100% children. Thirty per cent suffered from moderate to severe disability and 16.7% experienced relapses. Overall, two-thirds accrued the composite adverse outcome. On multivariate analysis, older age and anti-MDA5 predicted mortality. Arthritis, rash and positive ANA reduced and anti-MDA5 increased the risk for the composite adverse outcome. CONCLUSION: Indian patients with IIM suffer high early mortality attributable to infection, cancer and RP-ILD, calling for high vigilance post diagnosis. Autoantibodies and certain clinical features identify risk for composite adverse outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mehta P, Agarwal V, Gupta L, et al. High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India. Rheumatology (Oxford). 2021. PMID: 33493322. doi:10.1093/rheumatology/keab001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。